900,320 Shares in Becton, Dickinson and Company $BDX Purchased by Kingstone Capital Partners Texas LLC

Key Points

• Kingstone Capital Partners Texas LLC acquired a new stake in Becton, Dickinson and Company, purchasing 900,320 shares valued at approximately $155 million, which is 0.31% of the company.
• Other major investors such as GQG Partners LLC and Vanguard Group Inc. have also increased their stakes in Becton, Dickinson, with Vanguard holding over 28 million shares worth approximately $6.41 billion.
• Becton, Dickinson recently reported $3.68 EPS for the last quarter, exceeding estimates and marking a 10.4% revenue increase year-over-year, with a positive outlook for FY 2025 EPS guidance.

Kingstone Capital Partners Texas LLC purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 900,320 shares of the medical instruments supplier's stock, valued at approximately $155,080,000. Kingstone Capital Partners Texas LLC owned approximately 0.31% of Becton, Dickinson and Company as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in Becton, Dickinson and Company by 4.7% during the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier's stock valued at $6,414,322,000 after buying an additional 1,259,750 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its stake in Becton, Dickinson and Company by 3.7% during the first quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier's stock valued at $2,880,510,000 after buying an additional 448,644 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in Becton, Dickinson and Company by 10.8% during the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier's stock valued at $1,567,654,000 after buying an additional 667,957 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Becton, Dickinson and Company by 7.6% in the first quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier's stock worth $1,012,649,000 after purchasing an additional 312,124 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Becton, Dickinson and Company by 1.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 3,091,149 shares of the medical instruments supplier's stock worth $707,872,000 after purchasing an additional 37,733 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on BDX shares. Wall Street Zen upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Piper Sandler restated a "neutral" rating and issued a $200.00 price target (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Argus boosted their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Wells Fargo & Company boosted their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research note on Friday, August 8th. Finally, Barclays reduced their price objective on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research report on Tuesday, June 3rd. Four analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $213.30.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the company's stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director directly owned 22,226 shares in the company, valued at $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 2,965 shares of company stock valued at $551,536 over the last 90 days. Company insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX traded down $1.10 during trading on Friday, reaching $187.27. 2,750,943 shares of the company traded hands, compared to its average volume of 1,535,837. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The firm's fifty day simple moving average is $187.65 and its 200 day simple moving average is $190.16. The stock has a market cap of $53.68 billion, a P/E ratio of 33.68, a PEG ratio of 1.51 and a beta of 0.27.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.51 billion during the quarter, compared to analyst estimates of $5.50 billion. During the same quarter in the previous year, the business earned $3.50 EPS. Becton, Dickinson and Company's revenue for the quarter was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be given a $1.04 dividend. The ex-dividend date is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio is 74.82%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.